This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
RANGAP1 / Ran GTPase-activating protein 1 · IHC design guide
Design Immunohistochemistry for RANGAP1
Plan paraffin-section RANGAP1 IHC with the catalog antibody at 2–5 μg/ml (datasheet A02771-2). Assess nuclear, nuclear membrane and cytoplasmic staining against the tissue IHC profile (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
RANGAP1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Nuclei, nuclear membrane and cytoplasm (HPA tissue IHC) | |
| Staining pattern | All cells: nuclear, nuclear membrane and cytoplasmic staining (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A02771-2) | |
| Positive control | Adrenal gland+4 more · see all | |
| Negative control | None in HPA (detected in all 45 tissues); use no-primary + isotype controls |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across paraffin sections. (standard IHC practice; not target-specific) | |
| Caveat | SUMO-dependent nuclear pore targeting may alter the pattern (UniProt) | |
| Regulation | Testis-enhanced RNA expression (HPA tissue RNA) | |
| Isoform / epitope | No annotated isoforms; mature chain spans residues 2–587 (UniProt) |
Section 1
Recommended RANGAP1 IHC & IF Protocols
The catalog antibody’s IHC-P protocol is paired with published RANGAP1 IHC protocols for lymphoma, spinal cord, and brain sections (PMC3819250; PMC5427168; PMC5595097).
| Sample | Paraffin-embedded human colorectal cancer tissue; fixative not specified (datasheet A02771-2) |
| Fixation | Image fixative and duration unreported (datasheet A02771-2); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A02771-2); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A02771-2) |
| Primary antibody | Rabbit anti-RANGAP1, 2-5 μg/ml (datasheet A02771-2) |
| Primary incubation | Overnight at 4 °C (datasheet A02771-2) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet A02771-2) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | RANGAP1-positive staining in glandular cells of adrenal gland (HPA tissue IHC: High). HPA tissue profile: Distinct expression in the nuclei, nuclear membrane and cytoplasm in all cells. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA pH 8.0 retrieval for the catalog antibody (datasheet A02771-2); adjust using the published retrieval conditions for the relevant sample (PMC3819250; PMC5427168; PMC5595097).
Section 2
What Is the Expected RANGAP1 Staining Pattern?
RANGAP1 staining should be visible in nuclei, at the nuclear membrane and in cytoplasm across many cell types (HPA tissue IHC: Supported). Nuclear envelope enrichment during interphase and spindle or kinetochore association during mitosis are consistent with its annotated localisation (UniProt P46060). RANGAP1 has no transmembrane segment, so a nuclear rim should be read as nuclear envelope localisation rather than a membrane spanning pattern (UniProt P46060 topology).
| Nuclear membrane, nuclear and cytoplasmic staining is visible across cells, with strong signal in selected populations. | This fits the supported tissue IHC profile of distinct staining in these compartments across cells (HPA tissue IHC: Supported). High staining is reported in Purkinje cells, cortical neurons, bone marrow hematopoietic cells and several glandular or squamous epithelial populations (HPA tissue IHC: High). Compare intensity within the named cell population; a whole tissue label does not make every structure equally strong. |
| Signal appears only in an implausible compartment, while the expected nuclear rim and cellular staining are absent. | Check the control before assigning that pattern to RANGAP1: interphase nuclear envelope and cytoplasmic localisation are annotated (UniProt P46060), and tissue IHC includes nuclear, nuclear membrane and cytoplasmic staining (HPA tissue IHC: Supported). An isolated extracellular deposit is suspicious for an IHC artefact (general IHC interpretation); localisation alone cannot identify its cause. Assess mitotic cells separately because spindle and kinetochore association can occur (UniProt P46060). |
| The darkest deposits occur in an unexpected cell population or over tissue structures without cells. | First identify the cells on the counterstained section. HPA describes staining across cells, so an unfamiliar positive cell type is not automatically cross-reactivity (HPA tissue IHC: Supported). Conversely, deposits that disregard cell boundaries warrant checks for nonspecific antibody binding or endogenous detection activity (general chromogenic IHC practice). Compare the pattern with a known-positive cell population and the detection control before calling it target signal. |
| Diffuse colour covers nuclei, cytoplasm and surrounding tissue with little cellular contrast. | That appearance cannot establish the expected localisation, even when some genuine RANGAP1 is present (HPA tissue IHC: Supported; general IHC interpretation). Inspect a reagent control for chromogen generated without primary antibody, then review blocking, antibody concentration and wash conditions as general IHC variables. The supplied HPA and UniProt records do not identify a RANGAP1-specific source of diffuse background. |
| A named high-staining population has no detectable signal. | For example, Purkinje cells or bone marrow hematopoietic cells are reported as High (HPA tissue IHC: High). Verify that the relevant cells are present and that the detection run worked before interpreting absence as biological loss (general IHC practice). HPA reports low staining in adipocytes, so adipose tissue alone is a weak choice for judging whether a run can detect RANGAP1 (HPA tissue IHC: Low in adipocytes). |
💡Expected RANGAP1 appearanceCall a result positive when cell-associated nuclear membrane, nuclear and cytoplasmic staining is visible, with High signal possible in HPA-listed populations; isolated acellular deposits or colour unrelated to cell boundaries are suspect (HPA tissue IHC: Supported, High; general IHC interpretation).
| Cell-cycle stage (UniProt P46060) | During interphase, RANGAP1 is cytoplasmic and detectable at the nuclear envelope; after nuclear envelope breakdown it associates with kinetochores until late anaphase and with the mitotic spindle, but is essentially absent from spindle poles (UniProt P46060). Interpret a mitotic figure in that context before treating its departure from an interphase nuclear rim as aberrant. |
| SUMO-dependent localisation (UniProt P46060) | Sumoylation targets RANGAP1 to nuclear pores and is required for its annotated mitotic localisation (UniProt P46060). This supports a nuclear-envelope pattern but does not show that a particular stain can resolve individual pores or measure SUMO modification. The supplied sources give no target-specific antigen-retrieval or fixation-sensitivity result. |
| Tissue and cell selection (HPA tissue IHC) | HPA reports High staining in specified cell populations, including cerebellar Purkinje cells, cerebral cortical neurons and bone marrow hematopoietic cells, while adipocytes are Low (HPA tissue IHC). Its overall tissue IHC reliability is Supported, with high consistency between staining and RNA expression (HPA tissue IHC). These labels guide control selection; they are not an intensity threshold for every cell. |
| Antibody evidence (HPA antibodies) | HPA050110 and CAB004293 have Supported IHC entries; HPA062034 has no supplied IHC status (HPA antibodies). For an IHC-P result, use the IHC-supported evidence as the relevant comparison. A Supported status describes the listed antibody validation; it does not establish the performance of every antibody or detection system. |
| IF/ICC Q&A: What should a fluorescence cross-check show? | A mainly nuclear-membrane pattern is reported, with additional cytosol, vesicle and flagellar-centriole localisation (HPA subcellular ICC-IF). Those observations can help interpret compartment identity, but ICC-IF is a separate application and its additional locations are not required features of a chromogenic tissue section (HPA subcellular ICC-IF; HPA tissue IHC). |
| Situation | Likely cause | Next action |
|---|---|---|
| No signal in a control expected to stain strongly. | The control may lack the named cells, or a general IHC preparation or detection step may have failed (HPA tissue IHC: High; general IHC practice). | Confirm the cell population on the counterstain, verify the detection control, then review antigen retrieval and antibody dilution against the validated IHC-P instructions (general IHC practice). No RANGAP1-specific retrieval condition is supplied. |
| Only a broad nuclear signal is visible; the nuclear rim cannot be judged. | Dense colour or section detail may obscure compartment boundaries (general chromogenic IHC interpretation). Nucleoplasmic localisation is also annotated (UniProt P46060). | Inspect a well-preserved, less crowded field and compare nuclear edges with cytoplasm and counterstain (general IHC practice). Do not label nuclear staining alone a false positive; seek the fuller HPA tissue pattern where resolution permits (HPA tissue IHC: Supported). |
| Colour is widespread, including spaces between cells. | Nonspecific staining or endogenous detection activity can produce background in chromogenic IHC (general IHC practice). | Examine a no-primary detection control and review blocking, washes and antibody concentration using the validated IHC-P instructions (general IHC practice). Interpret RANGAP1 only where signal follows identifiable cells and plausible compartments (HPA tissue IHC: Supported). |
| A few mitotic cells differ sharply from neighbouring interphase cells. | RANGAP1 changes location during mitosis, including kinetochore and spindle association (UniProt P46060). | Identify mitotic figures on morphology and score them apart from interphase cells (general IHC interpretation). Do not demand an intact nuclear rim after nuclear envelope breakdown or spindle-pole staining as a positive criterion (UniProt P46060). |
| An unexpected cell population stains more strongly than the selected control population. | The observation may reflect cell identity, biological variation or nonspecific detection; HPA's broad cell staining profile alone cannot distinguish these (HPA tissue IHC: Supported; general IHC interpretation). | Recheck cell identity and localisation, compare a named High population on the same run, and examine the detection control (HPA tissue IHC: High; general IHC practice). Treat unexplained intensity differences as provisional. |
| An adipose-rich section appears almost negative. | Adipocytes are listed as Low, so a faint result there is compatible with the supplied tissue profile (HPA tissue IHC: Low in adipocytes). | Judge run sensitivity with a named High population, such as bone marrow hematopoietic cells or cerebellar Purkinje cells, and confirm those cells are actually present (HPA tissue IHC: High; general IHC practice). |
Experiment evidence
IHC & IF images showing RANGAP1 staining
A02771-2 · IHCIHC analysis of RANGAP1 using anti-RANGAP1 antibody (A02771-2). RANGAP1 was detected in a paraffin-embedded section of human colorectal canc
A02771-2 · IFIF analysis of RANGAP1 using anti-RANGAP1 antibody (A02771-2). RANGAP1 was detected in an immunocytochemical section of A431 cells. Enzyme a
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000100401-RANGAP1/tissue/cerebral+cortex#imid_1461496
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000100401-RANGAP1/tissue/colon#imid_1447546
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000100401-RANGAP1/tissue/liver#imid_1447563
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000100401-RANGAP1/tissue/kidney#imid_1447564
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody CAB004293; green = RANGAP1, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody CAB004293; green = RANGAP1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for RANGAP1 IHC & IF
🧪Run cerebellum first: Purkinje cells should stain (HPA: High in Purkinje cells). HPA detects RANGAP1 in all 45 scored tissues, so use no-primary and isotype controls instead of a negative tissue; no cell population on the positive slide is established as an internal negative, and any apparently unstained cells should be judged against control background (HPA: no negative tissue rows).
Positive control tissue: Adrenal gland (Glandular cells, HPA High)
Negative control tissue: None in HPA: RANGAP1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show RANGAP1 in A-431, U-251MG, U2OS, HEK293, MCF-7, RPTEC/TERT1, hTERT-RPE1 (serum starved), Sperm, KOLF2.1J, NIH 3T3, with annotated localisation: Nuclear membrane (supported) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only slide and a control with nonimmune rabbit IgG matched to the primary antibody’s isotype and clonality where applicable (caption: rabbit primary and goat anti-rabbit secondary; standard IHC practice). Use a RANGAP1 knockout specimen or immunizing-peptide block if available as a biological specificity control, and quench endogenous peroxidase before HRP/DAB detection (standard IHC practice; caption: HRP/DAB detection).
⚠️Feasibility: No target-specific fixation window or fixation effect is reported, and the selected A02771-2 paraffin-section caption does not state the fixative (caption: fixative unreported). The caption uses heat retrieval in EDTA at pH 8.0; test that condition for cerebellum, since the caption does not establish that retrieval is required in every tissue (caption: colorectal cancer IHC). The supplied evidence does not establish whether frozen sections or IF are easier; neuronal lipofuscin can cause autofluorescence if cerebellum is assessed by IF (standard IF practice).
HPA tissue IHC evidence for RANGAP1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Supported — High consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | High | Protein (IHC) | HPA → |
| Cerebellum | Purkinje cells | High | Protein (IHC) | HPA → |
| Cerebral cortex | Neuronal cells | High | Protein (IHC) | HPA → |
| Cervix | Glandular cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| None in HPA: RANGAP1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead. | ||||
Section 3
Advanced RANGAP1 IHC Tips
Troubleshoot RANGAP1 staining in paraffin-section IHC by checking retrieval, compartment-specific signal, controls, and scoring before interpreting intensity.
What retrieval should I try when RANGAP1 staining is weak?
Start with heat-mediated retrieval in EDTA buffer at pH 8.0 for paraffin sections (datasheet A02771-2). The selected image used that retrieval before overnight incubation at 4°C with 2 μg/ml primary antibody, so compare weak staining against that documented combination first (datasheet A02771-2). Keep retrieval time and heating method consistent across test and reference sections, and assess tissue damage alongside signal (standard IHC practice). If staining remains weak, test a second retrieval condition on adjacent sections while holding antibody concentration and detection constant; record both background and nuclear-envelope signal before adopting the change (standard IHC practice; UniProt P46060 localisation).
Could fixation explain weak or patchy RANGAP1 IHC?
RANGAP1-specific sensitivity to fixation is unknown from the supplied evidence; the selected paraffin-section caption does not state its fixative (datasheet A02771-2). Record the fixative, fixation duration, and processing history for each specimen, then compare sections processed together before changing the staining procedure (standard IHC practice). Include a reference section with reproducible nuclear-envelope and cytoplasmic staining, since those distributions are supported for RANGAP1 (HPA tissue IHC; UniProt P46060 localisation). If signal varies with processing, test matched specimens under controlled fixation conditions; do not attribute a particular fixation effect to RANGAP1 without that comparison (standard IHC practice).
Should I score nuclear, rim, and cytoplasmic staining together?
Score nuclear-envelope, nucleoplasmic, and cytoplasmic staining separately because the supported tissue profile includes all 3 distributions (HPA tissue IHC). Interphase RANGAP1 is cytoplasmic and can appear at the nuclear envelope, where sumoylation supports nuclear-pore targeting (UniProt P46060 localisation). A rim-like signal may therefore carry different information from diffuse nuclear staining; compare each compartment with matched controls and intact tissue morphology (UniProt P46060 localisation; standard IHC practice). In dividing cells, kinetochore and spindle association can change the pattern, so annotate mitotic figures rather than folding their signal into an interphase compartment score (UniProt P46060 localisation; standard IHC practice).
Could an isoform or modified epitope alter the IHC pattern?
The supplied RANGAP1 record annotates 0 isoforms, so an isoform-specific explanation for discordant staining has no support here (UniProt P46060 isoforms). RANGAP1 has annotated phosphorylation and SUMO-related regulation, including sumoylation associated with nuclear-pore and mitotic localisation (UniProt P46060 modified residues and localisation). The selected caption does not identify the antibody epitope or establish whether modification changes antibody binding (datasheet A02771-2). If compartment patterns disagree across antibodies, compare their disclosed immunogens and staining on adjacent sections, keeping retrieval and detection matched before proposing epitope masking or modification sensitivity (standard IHC practice).
How can IF help check an ambiguous chromogenic IHC pattern?
Use IF as a complementary localisation check for an ambiguous IHC compartment score, while evaluating its controls and antibody performance separately (standard IHC/IF practice). Multiplex RANGAP1 with a validated marker of the cell type being evaluated, then compare signal within marker-positive cells rather than across mixed tissue populations (standard IF practice). Choose a spectrally separated fluorophore, preferably toward the far-red when green tissue autofluorescence is prominent, and inspect unstained and single-label controls (standard IF practice). Because RANGAP1 has no annotated transmembrane segment and occurs in cytoplasmic and nuclear-envelope compartments, optimise permeabilisation for antibody access to those compartments without assuming a membrane-spanning epitope (UniProt P46060 topology and localisation; standard IF practice).
What should I adjust when DAB background obscures the nuclear rim?
The selected paraffin-section image used 10% goat serum blocking, a peroxidase-conjugated secondary antibody, and DAB development (datasheet A02771-2). Check a no-primary control for secondary-reagent binding and endogenous peroxidase, then apply a peroxidase block as part of the general chromogenic workflow (standard IHC practice). Compare background after changing one variable at a time, such as antibody concentration, blocking, washing, or DAB development time, while retaining the documented EDTA pH 8.0 retrieval as the starting point (datasheet A02771-2; standard IHC practice). Judge improvement by preservation of a distinct nuclear-envelope pattern, a supported RANGAP1 location (HPA subcellular; UniProt P46060 localisation).
How should I quantify RANGAP1 in paraffin-section IHC? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and score nuclear-envelope, nuclear, and cytoplasmic staining separately before calculating an H-score or percentage of positive cells (HPA tissue IHC; standard IHC practice). For an H-score, multiply the percentage of cells at each intensity by its intensity grade and sum the products; use the same thresholds across slides (standard IHC practice). Normalise each score to the number of evaluable cells in the stated compartment or cell population, and exclude damaged or necrotic areas (standard IHC practice). Report the denominator, compartment rules, and reference-section performance so differences in cell composition or staining run are visible (standard IHC practice).
How do I distinguish genuine RANGAP1 signal from staining artefact?
A credible pattern can include nuclear-envelope, nucleoplasmic, and cytoplasmic staining, with strong support for the nuclear membrane in subcellular imaging (HPA tissue IHC; HPA subcellular). Check whether signal follows intact cell boundaries and expected compartments; diffuse extracellular deposits or staining unrelated to identifiable cells warrant review against controls (UniProt P46060 localisation; standard IHC practice). Examine section edges and necrotic regions for uneven DAB deposition, and compare a no-primary control to identify endogenous enzyme or detection background (standard IHC practice). An unexpected cell population is not automatically negative, because the tissue IHC profile reports broad expression; verify cell identity and repeatability before assigning a biological interpretation (HPA tissue IHC; standard IHC practice).
Boster reagents
Best RANGAP1 / Ran GTPase-activating protein 1 IHC Antibodies
A02771-2 has IHC data from human colorectal cancer paraffin sections and IF data from A431 cells (catalog image captions); both listed antibodies react with human, mouse and rat (catalog reactivity).
Real IHC data
Anti-RANGAP1 Antibody ®
Cat # A02771-2
A02771-2 will render with its human colorectal cancer paraffin-section IHC image; its IF caption shows A431 cells (catalog image captions). M02771-1 will render as IHC- and IF/ICC-listed, with human, mouse and rat reactivity, but no IHC or IF image in the payload (catalog applications, reactivity and image fields).
Which to pick: Choose A02771-2 for paraffin-section IHC: its own caption documents EDTA pH 8.0 retrieval and 2 μg/ml primary antibody in human colorectal cancer tissue; the fixative is unreported (A02771-2 IHC caption). For IF/ICC, A02771-2 has an A431-cell IF image at 5 μg/ml, while M02771-1 is a rabbit monoclonal, clone 19R47, listed for IF/ICC without an image (A02771-2 IF caption; M02771-1 catalog). Both list human, mouse and rat reactivity, but the supplied tissue IHC image documents human tissue only (catalog reactivity; A02771-2 IHC caption).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P46060 (RAGP1_HUMAN, Ran GTPase-activating protein 1).
- Human Protein Atlas. RANGAP1 tissue IHC expression (reliability: Supported).
- Human Protein Atlas. RANGAP1 subcellular location (ICC-IF): Mainly localized to the nuclear membrane. In addition localized to vesicles, cytosol and flagellar centriole..
- Human Protein Atlas. RANGAP1 antibody validation summary (3 antibodies).
- The Ran GTPase-activating protein (RanGAP1) is critically involved in smooth muscle cell differentiation, proliferation and migration following vascular injury: implications for neointima formation and restenosis. PloS one 2014 — PMC4079658.
- Ran GTPase-activating protein 1 is a therapeutic target in diffuse large B-cell lymphoma. PloS one 2013 — PMC3819250.
- Mutant TDP-43 within motor neurons drives disease onset but not progression in amyotrophic lateral sclerosis. Acta neuropathologica 2017 — PMC5427168.
- Mutant Huntingtin Disrupts the Nuclear Pore Complex. Neuron 2017 — PMC5595097.
- PubMed PMID:7878053 — UniProt-cited evidence.
- PubMed PMID:11347906 — UniProt-cited evidence.
- PubMed PMID:12168954 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for RANGAP1 (Ran GTPase-activating protein 1). Expected localisation Nuclei, nuclear membrane and cytoplasm (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A02771-2). Validated IHC antibody: A02771-2 at 2-5 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Adrenal gland (Glandular cells); negative None in HPA (detected in all 45 tissues); use no-primary + isotype controls. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human colorectal cancer tissue; fixative not specified (datasheet A02771-2); 2. Fixation: Image fixative and duration unreported (datasheet A02771-2); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A02771-2); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A02771-2); 8. Primary antibody: Rabbit anti-RANGAP1, 2-5 μg/ml (datasheet A02771-2); 9. Primary incubation: Overnight at 4 °C (datasheet A02771-2). Watch for: Fixation: Keep fixation consistent across paraffin sections. (standard IHC practice; not target-specific); Caveat: SUMO-dependent nuclear pore targeting may alter the pattern (UniProt); Isoform / epitope: No annotated isoforms; mature chain spans residues 2–587 (UniProt); Regulation: Testis-enhanced RNA expression (HPA tissue RNA). Evidence: UniProt P46060, HPA tissue IHC · Supported, HPA ICC-IF · Mainly localized to the nuclear membrane. In addition localized to…, Datasheet A02771-2, PMC3819250, PMC5427168. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/RANGAP1/immunohistochemistry-ihc-guide.